ES2290161T3 - Derivados de quinolina. - Google Patents

Derivados de quinolina. Download PDF

Info

Publication number
ES2290161T3
ES2290161T3 ES01955382T ES01955382T ES2290161T3 ES 2290161 T3 ES2290161 T3 ES 2290161T3 ES 01955382 T ES01955382 T ES 01955382T ES 01955382 T ES01955382 T ES 01955382T ES 2290161 T3 ES2290161 T3 ES 2290161T3
Authority
ES
Spain
Prior art keywords
alkyl
compound
hydrogen
phenyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01955382T
Other languages
English (en)
Spanish (es)
Inventor
Chris Allen Broka
Woongki Kim
Kevin Lee Mclaren
David Bernard Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2290161T3 publication Critical patent/ES2290161T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES01955382T 2000-08-09 2001-08-01 Derivados de quinolina. Expired - Lifetime ES2290161T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22419600P 2000-08-09 2000-08-09
US224196P 2000-08-09

Publications (1)

Publication Number Publication Date
ES2290161T3 true ES2290161T3 (es) 2008-02-16

Family

ID=22839655

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01955382T Expired - Lifetime ES2290161T3 (es) 2000-08-09 2001-08-01 Derivados de quinolina.

Country Status (15)

Country Link
US (2) US7049325B2 (cg-RX-API-DMAC7.html)
EP (1) EP1313707B1 (cg-RX-API-DMAC7.html)
JP (1) JP3930428B2 (cg-RX-API-DMAC7.html)
KR (1) KR20030027016A (cg-RX-API-DMAC7.html)
CN (1) CN1199950C (cg-RX-API-DMAC7.html)
AR (1) AR033554A1 (cg-RX-API-DMAC7.html)
AT (1) ATE367379T1 (cg-RX-API-DMAC7.html)
AU (1) AU2001277560A1 (cg-RX-API-DMAC7.html)
BR (1) BR0113175A (cg-RX-API-DMAC7.html)
CA (1) CA2418832A1 (cg-RX-API-DMAC7.html)
DE (1) DE60129445T2 (cg-RX-API-DMAC7.html)
ES (1) ES2290161T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA03001178A (cg-RX-API-DMAC7.html)
WO (1) WO2002012192A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200300847B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW591089B (en) * 2001-08-09 2004-06-11 Cheil Ind Inc Slurry composition for use in chemical mechanical polishing of metal wiring
GB0220953D0 (en) * 2002-09-10 2002-10-23 Novartis Ag Organic compounds
US7132432B2 (en) * 2003-06-05 2006-11-07 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)
JP5667745B2 (ja) * 2005-03-08 2015-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大環状化合物を製造する方法
AU2009293493B2 (en) * 2008-09-17 2014-09-18 Boehringer Ingelheim International Gmbh Combination of HCV NS3 protease inhibitor with interferon and ribavirin
CN102596201A (zh) 2009-10-30 2012-07-18 贝林格尔.英格海姆国际有限公司 包含BI201335、干扰素α和利巴韦林的HCV组合治疗的用药方案
US9383448B2 (en) 2012-07-05 2016-07-05 Deca System Co., Ltd. Golf GPS device with automatic hole recognition and playing hole selection
CN117924243B (zh) * 2024-01-16 2025-09-12 沈阳药科大学 一种喹啉衍生物及其药用组合物和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9018134D0 (en) 1989-09-29 1990-10-03 Ici Plc Heterocyclic derivatives
ATE156120T1 (de) 1991-02-07 1997-08-15 Roussel Uclaf Bizyklische stickstoffverbindungen, ihre herstellung, erhaltene zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
GB9311790D0 (en) * 1993-06-08 1993-07-28 Minnesota Mining & Mfg Photothermographic materials
DK122693D0 (da) 1993-10-29 1993-10-29 Hempels Skibsfarve Fab J C Marin struktur
EP0830133A1 (en) * 1995-04-28 1998-03-25 Takeda Chemical Industries, Ltd. Therapeutic composition for arthritis
DE19638484A1 (de) * 1996-09-20 1998-03-26 Basf Ag Hetaroylderivate
DE19638486A1 (de) * 1996-09-20 1998-03-26 Basf Ag Hetaroylderivate
US6069151A (en) 1996-11-06 2000-05-30 Darwin Discovery, Ltd. Quinolines and their therapeutic use
IT1298159B1 (it) * 1997-01-28 1999-12-20 Hoffmann La Roche Derivati di un 5-aroilnaftalene
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6479438B2 (en) * 2001-01-04 2002-11-12 Isp Investments Inc. Gel inhibited liquid carrier for a biocide containing a carbodiimide and an emulsifier mixture

Also Published As

Publication number Publication date
EP1313707B1 (en) 2007-07-18
CA2418832A1 (en) 2002-02-14
US7186840B2 (en) 2007-03-06
AR033554A1 (es) 2003-12-26
US7049325B2 (en) 2006-05-23
BR0113175A (pt) 2004-02-17
JP2004505951A (ja) 2004-02-26
CN1199950C (zh) 2005-05-04
US20020082276A1 (en) 2002-06-27
WO2002012192A1 (en) 2002-02-14
CN1466575A (zh) 2004-01-07
MXPA03001178A (es) 2003-06-30
KR20030027016A (ko) 2003-04-03
US20060084677A1 (en) 2006-04-20
EP1313707A1 (en) 2003-05-28
ATE367379T1 (de) 2007-08-15
DE60129445D1 (de) 2007-08-30
ZA200300847B (en) 2004-04-30
JP3930428B2 (ja) 2007-06-13
AU2001277560A1 (en) 2002-02-18
DE60129445T2 (de) 2008-04-24

Similar Documents

Publication Publication Date Title
ES2238616T3 (es) Derivados de indol como inhibidores de cox ii.
ES2290161T3 (es) Derivados de quinolina.
EP1347963B1 (en) Benzofuran and benzothiophene derivatives as selective cox-2 inhibitors
JP3942897B2 (ja) ｐ−（スルホニル）アリール及びヘテロアリール
AU2002224890A1 (en) Benzofuran and benzothiophene derivatives as selective COX-2 inhibitors
JP2000513735A (ja) ５−アロイルナフタレン誘導体
AU2002342722A1 (en) Indole derivatives as COX II inhibitors
MXPA99006927A (en) 5-aroylnaphthalene derivatives